Genoway - Asset Resilience Ratio
Genoway (ALGEN) has an Asset Resilience Ratio of 0.00% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of Genoway to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2024)
This chart shows how Genoway's Asset Resilience Ratio has changed over time. See how leveraged is Genoway's balance sheet to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Genoway's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Genoway (ALGEN) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Genoway maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Genoway Industry Peers by Asset Resilience Ratio
Compare Genoway's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revolution Medicines Inc
NASDAQ:RVMD |
Biotechnology | 65.10% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Hugel Inc
KQ:145020 |
Biotechnology | 29.57% |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX |
Biotechnology | 39.07% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Absci Corp
NASDAQ:ABSI |
Biotechnology | 59.86% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
|
Lifecome Biochemistry Co Ltd
SHE:002868 |
Biotechnology | 4.69% |
Annual Asset Resilience Ratio for Genoway (2006–2024)
The table below shows the annual Asset Resilience Ratio data for Genoway.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | €0.00 ≈ $0.00 |
€31.80 Million ≈ $37.18 Million |
-- |
| 2023-12-31 | 1.64% | €523.40K ≈ $611.91K |
€31.84 Million ≈ $37.23 Million |
+1.75pp |
| 2022-12-31 | -0.11% | €-36.30K ≈ $-42.44K |
€32.92 Million ≈ $38.49 Million |
+0.00pp |
| 2021-12-31 | -0.11% | €-36.30K ≈ $-42.44K |
€32.50 Million ≈ $37.99 Million |
-- |
| 2020-12-31 | 0.00% | €0.00 ≈ $0.00 |
€27.57 Million ≈ $32.23 Million |
-- |
| 2019-12-31 | 0.00% | €0.00 ≈ $0.00 |
€19.15 Million ≈ $22.39 Million |
-- |
| 2018-12-31 | 0.00% | €0.00 ≈ $0.00 |
€19.69 Million ≈ $23.02 Million |
-- |
| 2017-12-31 | 0.01% | €1.48K ≈ $1.73K |
€17.17 Million ≈ $20.07 Million |
0.00pp |
| 2016-12-31 | 0.01% | €1.48K ≈ $1.73K |
€11.70 Million ≈ $13.68 Million |
+0.01pp |
| 2015-12-31 | 0.01% | €739.00 ≈ $863.97 |
€10.78 Million ≈ $12.60 Million |
0.00pp |
| 2014-12-31 | 0.01% | €739.00 ≈ $863.97 |
€10.38 Million ≈ $12.13 Million |
0.00pp |
| 2013-12-31 | 0.01% | €730.00 ≈ $853.45 |
€9.75 Million ≈ $11.40 Million |
-1.79pp |
| 2009-12-31 | 1.79% | €200.42K ≈ $234.31K |
€11.17 Million ≈ $13.06 Million |
-3.11pp |
| 2008-12-31 | 4.91% | €502.00K ≈ $586.89K |
€10.23 Million ≈ $11.96 Million |
-16.86pp |
| 2006-12-31 | 21.77% | €1.54 Million ≈ $1.80 Million |
€7.08 Million ≈ $8.27 Million |
-- |
About Genoway
genOway Société anonyme, a biotechnology company, engages in the development and commercialization of custom genetically modified mouse, rat, and cell line models worldwide. It produces customized mouse models, such as knockout (KO) and knockin (KI) mouse models; customized rat models, including constitutive and conditional KO, point mutation KI, and quick KI rat models; and customized cell lines… Read more